Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have characterised the effects of the recently described NMDA NR2B subtype selective antagonist, Ro 63-1908, on spontaneous behaviour and in tasks sensitive to non-selective NMDA antagonists. In both rats and wild type mice, Ro 63-1908 (1-30mg/kg sc) produced a mild increase in motor activity of lesser magnitude than that elicited by dizocilpine. No signs of overt
PCP
-like stereotypy were seen in either species at equivalent doses.
PPI
was also unaffected. However, in mice lacking the NR2A subunit, Ro 63-1908 (3-30mg/kg) produced a profound hyperactivity of similar magnitude to dizocilpine but few other '
PCP
-like' behaviours. In rats, Ro 63-1908 (1-10mg/kg) did not affect Morris water maze or delayed matching performance. In a 5-choice serial reaction time task, requiring rats to respond to a visual stimulus presented after a fixed time interval, Ro 63-1908 (0.3-3mg/kg) produced a dramatic increase in premature responses - accuracy was relatively unaffected. Finally in a DRL24 task, Ro 63-1908 (0.3-3mg/kg) reduced inter-response time, increased response rate, and consequently reduced efficiency. We conclude that the improved profile of Ro 63-1908 compared to NMDA channel blockers is due to both its selectivity for the NR2B vs. NR2A subunit containing receptors and its activity-dependent mechanism of action. However, in the 5-CSRT and DRL24 tasks, Ro 63-1908 produced behaviours suggestive of impaired response inhibition, implicating a critical role of NMDA NR2B transmission in this process.
...
PMID:Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. 1260 92
In the present study, we have investigated the effects of two selective 5-HT6 receptor antagonists, Ro04-6790 and Ro65-7199, in three drug-induced models of
PPI
disruption and on latent inhibition (LI) utilizing a conditioned lick suppression (CLS) procedure. Clozapine was included in each experiment for comparison. Neither Ro04-6790 nor Ro65-7199 (both 30 mg/kg) affected the
PPI
disruption produced by
PCP
(1.5 mg/kg s.c.), apomorphine (0.1 mg/kg s.c.), or LSD (0.1 mg/kg s.c.). There was also no interaction between each drug and CS preexposure in the CLS test indicating a failure of each drug to facilitate LI. In contrast, clozapine (12 mg/kg) attenuated an apomorphine and
PCP
-induced
PPI
deficit, although the
PPI
disruption produced by LSD was not significantly affected. At a lower dose of 5 mg/kg, clozapine also facilitated LI. Since each of these tests bear some predictive validity for the detection of antipsychotic drugs, the present studies do not support a therapeutic potential of 5-HT6 receptor antagonists in this regard.
...
PMID:Effect of the 5-HT6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine. 1287 17
Genetic differences in the neurochemical regulation of
PPI
in rats may help clarify the neural basis of inherited
PPI
differences in neuropsychiatric disorders. We reported and characterized substantial heritable differences in sensitivity to
PPI
-disruptive effects of DA agonists in outbred Sprague Dawley (SDH) versus Long-Evans (LEH) rats. Other strains might yield large group separations and facilitate studies of the neural basis for these strain differences; inbred strains might also allow us to map genes associated with differential
PPI
sensitivity. Sensitivity to the
PPI
-disruptive effects of the DA agonist apomorphine (APO) and the NMDA antagonist phencyclidine (
PCP
) were compared across inbred and outbred strains. APO sensitivity was greatest in SDH and buffalo rats, but the effect in buffalo rats was complicated by significant APO-induced startle suppression.
PPI
APO sensitivity was least in ACI and LEH rats; F344s exhibited intermediate sensitivity and Lewis rats showed a nonlinear dose response (sensitivity at low but not higher doses).
PPI
APO insensitivity in ACI rats developed over time, with ACI pups exhibiting robust sensitivity. Substantial strain differences were observed in short-interval (10-30 ms) prepulse effects, and APO-induced increases in short-interval
PPI
occurred in SDH, LEH, and Lewis rats, but not in F344, ACI, or buffalo rats. Sensitivity to
PPI
-disruptive effects of
PCP
was generally greater in outbred than inbred rats. These findings identify strains suitable for comparisons of
PPI
neural circuitry and others for whom such comparisons would be complex and perhaps less informative.
...
PMID:Sensitivity to drug effects on prepulse inhibition in inbred and outbred rat strains. 1475 57
Prepulse inhibition of startle ('
PPI
'), a cross-species measure of sensorimotor gating, is impaired in schizophrenia patients. Suppression of P50 event-related potentials (ERPs) in response to the second of two clicks ('P50 gating') is also impaired in schizophrenia. Suppression of N40 ERPs to the second of two clicks ('N40 gating') is thought by some to be a rat homolog of human P50 gating. Emerging evidence suggests differences in the neurobiology of deficits detected by
PPI
vs P50 (or N40) gating. We recorded
PPI
and N40 gating contemporaneously in rats, to assess convergence and divergence in the neurochemical regulation of these measures. Dose-response studies examined the effects of apomorphine (APO), phencyclidine (
PCP
) or the 5HT2A agonist DOI on
PPI
, and on motor responses to stimuli (S1 and S2) that elicit N40 gating. Effects of optimal drug doses on
PPI
and N40 gating were then assessed in other rats with implanted cortical surface electrodes. APO,
PCP
and DOI caused dose-dependent disruptions of both
PPI
and gating of motor responses to N40 stimuli. Reduced
PPI
reflected diminished prepulse effectiveness, demonstrated by increased startle levels on prepulse+pulse trials. In contrast, reduced gating of motor responses to N40 stimuli reflected a reduced motor response to S1. In separate rats, robust
PPI
, N40 potentials and N40 gating could be detected within one test.
PPI
and N40 gating were disrupted by APO,
PCP
, and DOI. Again, drug effects on
PPI
reflected increased startle on prepulse+pulse trials, while those on N40 gating reflected reduced ERP responses to S1. In conclusion, when
PPI
and N40 gating were studied concurrently in rats, drug effects on
PPI
reflected reduced inhibition of startle by the prepulse, while diminished N40 gating reflected S1 response suppression. Despite similarities in drug sensitivity, these results suggest that distinct neurobiological mechanisms underlie drug-induced deficits in
PPI
and N40 gating.
...
PMID:Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. 1612 72
Deficits in pre-pulse inhibition (
PPI
-indicative of psychosis in humans) can be replicated in rats using the NMDA receptor antagonist phencyclidine (
PCP
). Ultrasonic vocalisations (USVs) produced by rats in response to acoustic startle are indicative of heightened anxiety; here we tested the predictive validity of USVs as an indicator of
PPI
. Male juvenile Sprague-Dawley rats (n=10) were treated for 14 days with either
PCP
(5mg/kg i.p.) or saline controls (1 ml/kg i.p.).
PPI
responses and USVs were recorded on days 16 and 19.
PCP
-treated rats showed decreased
PPI
performance on day 16 compared to controls; an observation that was unexpectedly reversed on day 19. Call parameters indicated that both treatment groups experienced similar levels of anxiety in response to the
PPI
paradigm on day 16. On day 19, the controls showed increased call duration and latency to onset (LtO) of calling, but decreased in the total number of calls produced compared to day 16. The calling period was significantly reduced compared to
PCP
-treated animals on say 19, whilst the LtO and duration were significantly increased. These changes were considered indicative of heightened levels of anxiety, most likely due to inadvertent fear conditioning (supported by reduced
PPI
performance) acquired during
PPI
testing. In contrast, the stability of USV characteristics emitted by
PCP
treated animals likely signified the detrimental effects of chronic
PCP
treatment on working memory. These results suggest that USVs are a valuable additional measure during
PPI
testing, helping to explain the unexpected results from our control group.
...
PMID:Ultrasonic vocalisations explain unexpected effects on pre-pulse inhibition responses in rats chronically pre-treated with phencyclidine. 1946